NCT03617198View on ClinicalTrials.gov

CD4 CAR+ ZFN-modified T Cells in HIV Therapy

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 31, 2019

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Hiv
Interventions
BIOLOGICAL

CD4 CAR+CCR5 ZFN T-cells

A dual cohort, open-label, randomized study of the safety and tolerability of a single infusion of autologous T cells genetically modified to express a CD4 chimeric antigen receptor while also having zinc finger nuclease-mediated disruption of the CCR5 gene

Trial Locations (1)

19104

University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

University of Pennsylvania

OTHER